BIOMARIN PHARMACEUTICAL INC (BMRN) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-05-11

Key Insights

EVP and Chief R&D Officer Gregory R. Friberg sold 3,281 shares of BMRN at $53.85 per share on May 7, 2026, reducing his direct holdings to 51,818 shares, indicating a modest insider sale rather than accumulation.
The sale represents approximately 5.9% reduction in this executive's holdings, which is a moderate level of insider selling that could suggest either portfolio rebalancing or reduced confidence in near-term stock appreciation.
As a senior R&D executive, Friberg's selling activity may warrant monitoring as insider R&D leadership sentiment can signal confidence levels in the company's pipeline and scientific strategy.

Want the newest filings?

This analysis covers the filing from 2026-05-11. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-03-19

George Eric Davis, the EVP and Chief Legal Officer of BioMarin Pharmaceutical Inc., disposed of 1,273 shares of the company's common stock on March 18, 2026 at a price of $56.05 per share.
This transaction reduced Davis's direct beneficial ownership of BioMarin's common stock to 78,560 shares.
Insider selling can sometimes signal a lack of confidence in the company's future performance, but a single transaction may not be indicative of a broader trend.

Filed: 2026-03-19

Charles Greg Guyer, the EVP and Chief Technical Officer of BioMarin Pharmaceutical Inc., sold 1,693 shares of the company's common stock on March 17, 2026 at $56.05 per share.
Following the reported transaction, Guyer still holds 84,140 shares of BioMarin common stock directly.
This insider sell transaction, while not a large amount, could be seen as a somewhat negative signal about the executive's confidence in the company's short-term prospects.

Filed: 2026-03-19

Brian Mueller, the EVP and Chief Financial Officer of BioMarin Pharmaceutical Inc. (BMRN), disposed of 2,117 shares of the company's common stock on March 17, 2026 at a price of $56.05 per share.
Following this transaction, Mueller's direct beneficial ownership in BMRN decreased to 123,314 shares.
This insider sale, while not a large transaction, may indicate that the executive has a moderately positive sentiment about the company's current valuation and future prospects.

Filed: 2026-03-19

The reporting person, Alexander Hardy, is the Chief Executive Officer of BioMarin Pharmaceutical Inc. and a director, indicating his influential role in the company's leadership and operations.
Alexander Hardy disposed of 4,252 shares of BioMarin's common stock on March 17, 2026, reducing his direct beneficial ownership to 214,635 shares.
The transaction was executed at a price of $56.05 per share, which may provide insights into the market's perception of BioMarin's stock value at the time.

Filed: 2026-03-18

The reporting person Gregory R. Friberg, EVP and Chief R&D Officer, acquired 19,150 shares of common stock through restricted stock units on March 16, 2026.
Friberg also disposed of 1,629 shares of common stock through a sell-to-cover transaction on March 17, 2026 at a price of $56.05 per share.
Friberg now holds 55,099 shares of common stock directly, representing his total beneficial ownership in the company.

Filed: 2026-03-18

Cristin Hubbard, the EVP and Chief Commercial Officer of BioMarin Pharmaceutical Inc. (BMRN), acquired 15,410 shares of common stock through a restricted stock unit grant on March 16, 2026.
Hubbard also disposed of 1,245 shares of common stock through a tax withholding transaction on March 17, 2026, at a price of $56.05 per share.
Hubbard's total direct ownership in the company increased to 44,790 shares following the reported transactions.

Filed: 2026-03-17

Brian Mueller, the EVP and Chief Financial Officer of BioMarin Pharmaceutical Inc., acquired 18,740 additional shares of the company's common stock through a restricted stock unit grant on March 16, 2026.
Mueller disposed of 9,945 shares of BioMarin common stock on March 13, 2026, likely to cover tax withholding obligations related to the vesting of equity awards.
The reported transactions indicate that the CFO is maintaining a significant direct ownership position in the company, aligning his interests with those of shareholders.

Filed: 2026-03-17

The reporting person, Charles Greg Guyer, the EVP and Chief Technical Officer of BioMarin Pharmaceutical Inc., acquired 14,990 additional shares of the company's common stock on March 16, 2026 through a restricted stock unit grant.
Guyer also disposed of 9,109 shares of the company's common stock on March 13, 2026, likely to cover tax withholding obligations related to the vesting of equity awards.
Guyer's total direct holdings in BioMarin Pharmaceutical increased from 70,843 shares to 85,833 shares following the reported transactions, indicating his continued commitment to the company.

Filed: 2026-03-17

George Eric Davis, the EVP and Chief Legal Officer of BioMarin Pharmaceutical, acquired 14,570 shares of the company's common stock through restricted stock units on March 16, 2026, increasing his direct beneficial ownership to 79,833 shares.
Davis also disposed of 7,177 shares of the company's common stock on the same date, likely for tax withholding purposes associated with the restricted stock unit vesting.
The reporting person's direct holdings have been adjusted by 13 shares to correct a previous clerical error, indicating the company's attention to detail in its reporting.

Filed: 2026-03-17

The CEO Alexander Hardy has acquired a significant number of 62,440 shares of BioMarin Pharmaceutical, indicating his confidence in the company's future performance.
The CEO has also exercised stock options for 89,200 shares, further increasing his stake in the company.
The insider buying activity, combined with the CEO's existing holdings of 156,447 shares, suggests strong leadership alignment with shareholders' interests.

Other reports for BIOMARIN PHARMACEUTICAL INC

Quarterly Report Current Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.